Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Crown Castle International Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Crown Castle International Corp trades at $76.47 (market cap $33.70B). The key difference: Crown Castle International Corp is far larger — about 7.5× ACADIA Pharmaceuticals Inc.'s market cap, and Crown Castle International Corp pays a 5.5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CCI | |
|---|---|---|
Market Cap | $4.49B | $33.70B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $113.91 |
52-Week Low | $20.06 | $74.92 |
Enterprise Value | $3.69B | $63.53B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Crown Castle (CCI) trades at $77.22, up 0.81% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q1 2026 miss but strong beats in prior quarters, while the company transitions to a pure-play U.S. tower focus after divesting its fiber business. Cash flow remains positive, but high debt levels and negative shareholder equity pose challenges. The stock is near its 52-week low, with a consensus price target of $97.33 suggesting significant upside potential.
The outlook for CCI hinges on execution of its strategic refocus and cost reductions. Opportunities include a 5.55% dividend yield and analyst optimism, but risks from elevated leverage and competitive pressures in telecom infrastructure warrant caution. Investor sentiment is divided, with technical indicators signaling near-term weakness despite long-term value arguments from bulls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
